Project Alert

Activation Capital, a nonprofit affiliated with the 34-acre VA Bio+Tech Park, has filed plans with the city of Richmond to build a six-story, 100,000-square-foot research building at 706 E. Leigh St. The building will occupy a roughly 2-acre block bounded by East Jackson, East Leigh, North Seventh and North Eighth Streets. Plans also show a 740-space parking deck. The project  awaits city approval. The property is already zoned with the same designation as other properties in the park, meaning it likely won't require a rezoning or special-use permit. Learn More

Backed by venture capital firm Pillar, Petri has a three-year $15 million commitment to back companies developing new biotech applications, along with the enabling technologies to bring these products to market. Pillar has already invested in a couple of companies that show the potential promise of new biotech research coming from Boston-based universities, like Boston University, Harvard and the Massachusetts Institute of Technology. Over time, the accelerator expects to have 10 to 20 companies in each market segment as the program expands. In addition to checks of at least $250,000 the Petri accelerator has lab and office space available for each company. Learn More

Pfizer has made public plans to establish a digital research hub with a focus on artificial intelligence and big data analytics in Thessaloniki, Greece. The Thessaloniki hub is part of a planned multinational network of digital research centers to develop technology that can be incorporated into Pfizer's development pipeline of medicines and vaccines. The biopharma giant expects the facility, the first of six, to become operational in 2020, providing up to 200 jobs. The recent announcement comes as a surprise to some due to the lack of biopharma on the island nation. However, Pfizer CEO Albert Bourla is a native of Greece, specifically Thessaloniki, Greece. Learn More

An India-based subsidiary of Sanofi said it will sell a manufacturing plant in Ankleshwar, Gujarat, to Advent International's Zentiva for about $37 million. The site is Sanofi's oldest manufacturing facility in India and produces medications including Combiflam, Allegra and Amaryl. Production of those products will be moved to other sites including in Goa, according to a Sept. 11th Sanofi release posted to India's stock exchange. The agreement builds on a much larger deal from last year, when Advent paid $2.1 billion, for Sanofi's European generics business, Zentiva. Now, a Zentiva unit in India is taking over the Ankleshwar site, which manufactures more than 6 billion tablets a year. Learn More

The Rock Creek Property Group has secured a $34 million loan for the conversion of a former manufacturing facility in Gaithersburg, Md., into a life science property. The property, built in 1973, sits on a 13-acre plot and will be converted into a 120,000 sq. ft. Class A life science building outfitted for one tenant. Rock Creek purchased the former manufacturing facility - at 700 Quince Orchard Road in Gaithersburg - from DRS Solutions in 2015 for just $5 million. The speculative conversion will establish the first floor of the building as a parking garage, and the build out and business plan will aim to house just one tenant, although it "breaks nicely from two to four ," Learn More

The UC Santa Cruz Genomics Institute is moving off campus and into the middle of a growing biotech hub on the city's westside. In a new 11,000-square-foot headquarters in a renovated office building at 2300 Delaware Ave., the Genomics Institute is hoping to find firm footing for its work in Santa Cruz's growing biotech corridor. Biotech incubator Startup Sandbox, a university-affiliated nonprofit, is just blocks away on Natural Bridges Drive. Budding biotech startups Claret Bioscience, NantOmics and Ontera are just around the corner. Prior to this summer, the institute was spread out across five sites on the sprawling university campus. Learn More

Morgan Sindall Construction has won a $23 million contract to build a new headquarters for Eli Lilly and Company in Basingstoke, UK. Located within the Basing View Enterprise Zone, the 45,000 sq ft five-story commercial building will provide Grade A workspace and a new home to the biopharma giant. The main contractor is carrying out the work for Basingstoke and Deane Borough Council, and Morgan Sindall Group sister company, Muse Developments. Designed by architect TP Bennett, the building will be owned by the borough council and will be the second-largest commercial asset in its portfolio. Learn More

The Westchester County Industrial Development Authority has given preliminary approval for a tax exemption on a $38.2 million biotech project in Ardsley, New York. BioMed Realty plans to complete two shell buildings at 430-440 Saw Mill River Road, next to the Accorda Therapeutics labs and offices on its Ardsley Park campus. The developer says it is targeting small life science companies that cannot afford the costs of outfitting expensive labs. To that end, BioMed is willing to lease as little as 5,000 square feet to smaller enterprises. The vacant structures in Ardsley contain a total of 97,000 square feet. Learn More

In May, Thomas Jefferson University opened the doors to a Philadelphia first - the Jefferson Institute for Bioprocessing (JIB). With the potential to help fill the local workforce gap, JIB is the only bioprocessing training institute in the country where students can engage in a range of workshops, training and academic programs modeled after the National Institute for Bioprocessing Research and Training (NIBRT) curriculum. Located in Spring House Innovation Park in Lower Gwynedd, Pennsylvania, the JIB gives scientists, engineers and technicians access to a state-of-the-art bioprocessing training facility where they can practice complex bioprocessing procedures using industry-grade equipment. Learn More

Strides Pharma this week announced that it has acquired a drug manufacturing facility in Riviera Beach, Florida from Micelle BioPharma. The financial details of the deal have Strides paying $500K for the facility and planning to invest upwards of $10 million to expand the sites capabilities. According to published reports, the manufacturing facility has undergone multiple inspections by the U.S. FDA over the years and has no outstanding observations. It joins eight other formulation sites distributed globally that are operated by Strides. Learn More

As it closes in on one of the most valuable land deals in Seattle history, Alexandria Real Estate Equities is betting that biotech can thrive in a real estate market dominated by big tech. The real estate firm recently reached an agreement with the city of Seattle to buy the Mercer Mega Block, a trio of development sites that lie between Amazon's campus and the cluster of life sciences institutions around Lake Union. It's the latest in a long line of bets made by Alexandria on Seattle's life science industry. Alexandria plans to pay $143.5 million for the site, roughly 40 percent above the original bid. Learn More

Pfizer is investing $500 million to expand its manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy. The investment will add additional capacity and capabilities to a facility that makes some of Pfizer's most closely watched experimental treatments. The Sanford plant manufactures therapies used for the company's late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies. It is also responsible for making components for some of Pfizer's vaccines, such as Prevenar 13, which had nearly $6 billion in sales in 2018. Learn More

Caris Life Sciences has unveiled plans to develop the Caris Life Sciences Corporate Park in Irving, Texas, adding to the company's growing footprint in the United States. This new facility will enable approximately 115,000 square feet of new R&D laboratory and office space, and create more than 500 new job opportunities. Within the new Caris Life Sciences Park, employees will work to substantially expand the company's blood-based diagnostic assays as well as blood-based molecular profiling and increase research and development capacity. Learn More

Biopharma will officially open its new blood fractionation facility near the Ukrainian city of Kiev next month. The construction of the site, and subsequent commissioning, took roughly four years to complete and cost $75 million. The plant utilizes industry leading bioprocess solutions from Stilmas, Olsa, GEA Westfalia, General Electric, Pall, and Steriline.  According to published reports, the facility will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Learn More

The Colorado Economic Development Commission agreed this week to offer up to $24.8 million in tax and other incentives in hopes of persuading an unnamed biotech company to open a campus in Boulder County and create 1,000 well-paid jobs. According to reports the unidentified company already operates at four sites in Colorado, but if it accepts Colorado's tax credit offer it would consolidate in Boulder County. Estimates value the project at upwards of $130 million. However, other states are being considered as potential locations for the site including Minnesota, Tennessee and Texas. Learn More

Regeneron is planning to build a four-story, 256,000+ sq. ft. structure known as the Science Building at its Tempel Lane campus in Albany, New York. The building, which will house both labs and offices, would be the third and final phase of expansion at Regeneron's campus. The project will be managed by the Boston office of the engineering and construction firm Jacobs. Alert readers will recall that Regeneron has been investing heavily into its Albany site. This includes construction of a 212,000 sq. ft. warehouse and the ongoing project to build a 346,000 sq. ft. manufacturing facility at the site. This latest project is expected to take 30-36 months to complete. Learn More

Aldevron has been granted the $5 million tax break it sought to help facilitate the expansion of its existing facility and the building of a new facility. Specifically, the building of a new, state-of-the-art, 180,000 square foot biologics manufacturing facility and a 20,000 square foot expansion of their existing facility in Fargo, North Dakota. According to published reports, the estimated budget for the project is $72 million, which includes both construction of the buildings as well as procurement of associated equipment. This is a big win for Fargo which faced competition from others seeking to be the site of Aldevon's new facility. Learn More

Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary plans to employ 300 staff in its new Norton plant by 2021. While the project is still in the preliminary stages, the cell and gene therapy firm plans to fund the new plant with tax increment financing (TIF), a public financing method used for redevelopment. Brammer currently employs around 600 people in various locations, so will be increasing its staff by 50%. Learn More

Adaptive Biotechnologies has announced plans to lease a new 100,000 sq. ft. corporate headquarters with a state-of-the-art office space and research facility that will triple the company's Seattle footprint.  The biotech's current headquarters, 1551 Eastlake Avenue East, also part of The Eastlake Life Science Campus by Alexandria, is a short distance from the future facility. Shell construction of the new building is expected to be completed in 2020 and Adaptive plans to occupy the new building in 2021 once interior construction is finished. Learn More

CSL has made public plans to move into a new 16 story corporate headquarters, complete with state-of-the art laboratories, near the Parkville biomedical precinct which includes the University of Melbourne, several hospitals and top research facilities such as the Doherty Institute for Infectious Disease. The 376,000 sq. ft. development, which is yet to be given final planning approval, will accommodate more than 800 CSL employees including early stage research and product development teams and its commercial and corporate staff across seven floors of office space and nine floors of laboratories and research and clinical phase production suites. Learn More

HarkerBio is holding a web-based auction today to sell off its collection of biotechnology equipment. The Buffalo-based biotech company ceased operations earlier this year. Its sole secured creditor is the Erie County Industrial Development Agency, which approved the company for a low-interest $500,000 loan. Equipment from industry leading suppliers including Agilent, Bio-Rad, Eppendorf, Thermo Scientific and others are part of this auction.  Learn More

Fujifilm has announced that it has completed the acquisition of Biogen's large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark for roughly $890 million in cash. With the closing of this transaction, the Hillerød Manufacturing site is now the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies. Hillerød Manufacturing will change its name to FUJIFILM Diosynth Biotechnologies Denmark ApS once all regulatory procedures are complete. The new site consists of a campus hosting a large-scale production facility equipped with 6 x 15,000L bioreactors for the manufacture of cell culture derived biologics for clinical and commercial use. Learn More

Mylan has made public plans to exercise its option to acquire the Novartis manufacturing site at 150 Industrial Road in San Carlos, California. The site, which has had several owners over the last 12 years, was acquired by Novartis with the purchase of Nektar in 2008. The option to acquire the site was obtained by Mylan when it purchased Novartis' cystic fibrosis products for $460 million in 2018. While terms of the deal have not been disclosed, published reports note that Mylan is expected to hire the roughly 100 people employed at the site. Alert readers will recall that Mylan recently agreed to merge with Pfizer's generics business, of which this site will be a part. Learn More

Alexandria made public this week that it is considering developing an up to 650,000-square-foot campus at 5, 10 and 15 Necco St. in Boston's Fort Point neighborhood. The company's leadership, on a conference call this week to discuss earnings, went on to note that construction of the project could begin as early as next year on the biopharma property next to the future world headquarters of GE. Alexandria has invested heavily in the Fort Point area, spending roughly $250 million for a 2.7 acres parcel of land and another $80 million on a parking garage. Learn More

Genmab A/S has signed a long-term lease on a building at 777 Scudders Mill Road in Plainsboro, New Jersey that will serve as its U.S. headquarters office and host research lab. In doing so, Genmab becomes the first new tenant at the campus since the relocation of Bristol-Myers Squibb. Genmab will move into 90,070 square feet across two floors in a consolidation and expansion of its office and research activities in the United States. The 125-acre campus was custom-built for biopharma giant Bristol-Myers Squibb and consists of three, five-story, 220,000-square-foot office buildings. Learn More

Pennsylvania Biotechnology Center's start-up "incubator," which has grown up around Doylestown's Baruch S. Blumberg Institute for cancer and hepatitis research, says it's raising a $50 million investment fund and adding a second, 50,000-square-foot building and a bio-accelerator program to attract new drug and medical device firms to its Bucks County campus.  The fund, dubbed Hatch BioFund Management LLC, will be run by former West Pharma executive turned investment banker Vladimir Walko.  Learn More

Pall Corporation has been chosen by Servier as an exclusive technology and services provider for their Gidy, France biomanufacturing facility. End-to-end solutions from Pall Biotech will be implemented for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins. The facility is part of the Bio-S project at Servier focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale. The Bio-S project at the Gidy facility includes production lines to support internal production needs with up to 2,000L bioreactor capacity that can be run in a parallel format. Learn More

Precision BioSciences has announced the opening of its production facility for in-house manufacturing. Calling it the Manufacturing Center for Advanced Therapeutics (MCAT), Precision touts the facility as "the first in-house current Good Manufacturing Process (cGMP)-compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf chimeric antigen receptor (CAR) T cell therapy products." Currently, the new facility is undergoing CQV (commissioning, qualification, and validation) in preparation for cGMP manufacturing to begin in the fourth quarter of 2019. With the MCAT opening, Precision still has plenty of room to grow. Learn More

A deal-making cancer doctor who sold his biopharma company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry. Arie Belldegrun's family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said in a statement. The venture said it bought its first property, a 1 acre development site at 105 West First St. in the Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco. The Seaport District site comes with 250,000 square feet of development rights and is expected to be finished by 2021. Learn More

Vaxine has made public plans to move into the former VGTI building in Port St. Lucie, Florida. The vaccine lab, owned by the city since 2017, is located along Interstate 95. Port St. Lucie had been marketing the 107,000-square-foot lab as the Florida Center for Bio-Sciences. Vaxine will join the Cleveland Clinic in occupying the facility. While Vaxine is based in Australia, it has three research grants from the National Institutes of Health totaling $7.2 million. One award is for work on a flu vaccine. Another is for a tuberculosis inoculation. Learn More

Nexus Pharmaceuticals has announced an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading sterile injectable manufacturing facility. The multi-phase, multi-year project is expected to be completed in ten years, with an estimated investment of $250 million. Construction is planned to commence in August 2019 and is expected to be completed in 2021. The initial phase 1 investment of $85 million will support a new, 100,000 square foot three-story manufacturing facility. The facility is being designed by Integrated Project Services (IPS) with construction management services being provided by Turner Construction. Learn More

Charles River Laboratories has announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020. CRADL provides flexible, turnkey vivarium rental space supported by Charles River's technical, vivarium, and veterinary support expertise in key biohubs. Initially launched in downtown Cambridge, Massachusetts, CRADL Cambridge offers rental vivarium space for emerging and well-established research institutions. Similar to its sister facility in Cambridge, CRADL South San Francisco will focus on providing a turnkey vivarium solution and in vivo support services for researchers looking to divert more time and resources to their research. Learn More

Alloplex Biotherapeutics, which is working to develop an individualized cellular therapy to treat cancer, is relocating from an incubator at SmartLabs in Cambridge to a 4,700-square-foot facility at TradeCenter 128 in Woburn. The cellular therapeutics company is expected to move in September to the Cummings Properties-managed campus. The landmark TradeCenter 128 campus directly fronts I-95 and is one mile from the I-93 interchange. Several other life science firms-including Quest Diagnostics, OpGen, Batavia Biosciences, and Sophion Biosciences-lease space at this property. Learn More

Citra Labs has unveiled its $30 million, 60,000 square foot, newly renovated manufacturing facility on Messina Drive in Braintree, Massachusetts. The Life Science Corridor Initiative is a partnership created by the mayors of Boston, Cambridge, Quincy, Somerville and Braintree which seeks to bring life science companies to the communities of the Red Line corridor. The communities hope to do this through collaboration with leaders in education, government and life sciences to foster continued success in research, innovation and business development. Learn More

Lonza has announced that it will acquire a sterile drug product fill & finish facility from Novartis. The facility, located in Stein, Switzerland, will be the first for the facility for Lonza's Drug Product Services (DPS). No employees are expected to lose their jobs with the deal. The site will be the first Lonza DPS facility to cover sterile manufacturing for clinical production and commercial launches, the company said. The new facility will help Lonza Pharma & Biotech build on existing parenteral drug product development and testing capabilities. It will be the first sterile drug product fill and finish facility in Lonza's network. Financial terms of the deal were not disclosed. Learn More

Johnson & Johnson has announced the opening of JLABS in Shanghai, the world's largest JLABS and the first in Asia Pacific. The roughly 47,000 sq. ft. facility, located in Shanghai's Zhangjiang Hi-Tech Park, is a collaboration with the Shanghai Pharma Engine Company, Ltd. The site can accommodate more than 50 start-ups across the pharmaceuticals, medical device, consumer and health tech segments, and opens with 31 resident companies, including the three awardees of the Lung Cancer Innovation QuickFire Challenge. Learn More

Mile High Labs, the largest manufacturer of CBD isolate in the world, has announced the purchase of Novartis' 400,000 square foot production facility in Broomfield, Colorado. The transaction includes the land, labs, building, and ready-to-use finished products manufacturing equipment. The Broomfield facility is fully operational, which allows Mile High Labs to begin production in the near term of private label products including tinctures, capsules, tablets, topicals, and gummies. The facility includes equipment and infrastructure for research and development, quality assurance, bottling, filling, packing, warehousing, labeling, shipping and compliance monitoring. Learn More

Selkirk Pharma has made public plans to build a new, roughly $30 million manufacturing facility near Spokane, Washington. The predevelopment application filed with the city of Spokane indicates the company plans to build a 63,000-square-foot manufacturing facility on over 6 acres of land at 9110 W. Granite, in the southwest section of the Pacific Northwest Technology Park, across Granite from the large Northwest Farm Credit Services headquarters building in West Plains, Washington. The manufacturing facility will employ the VarioSys sterile filling system from Bausch+Stroebel and both a Skan isolator and the new Skanfog technology from Skan AG. Learn More

Bristol-Myers Squibb and Catalent have announced that Catalent has agreed to purchase BMS's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions. Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from BMS. Upon closing, Catalent will continue to manufacture Bristol-Myers Squibb's current product portfolio at the site. Learn More

AstraZeneca's new global headquarters in Cambridge, UK is now estimated to cost $950 million. That is roughly twice the estimated cost when the project kicked-off several years ago. According to AZ's latest annual report, the increased costs can be attributed to the complexity of the architecture, general inflation in construction costs and "increased investment in new technologies and equipment". While occupancy of the new site was originally planned for 2016, the latest schedule has occupancy starting in 2020 with the site not being fully operational until after 2020. Learn More

KriGen Pharmaceuticals is investing $7 million and hiring 100 employees at its new manufacturing facility and quality control lab in the Harnett County community of Lillington, about 30 miles south of Raleigh. The 55,000-square-foot site is being designed to manufacture a variety of sterile liquid injectable products for hospital and clinical use, using current good manufacturing practices (cGMP) to ensure safety and effectiveness. The North Carolina Biotechnology Center provided expert support in the recruitment of KriGen. Learn More

Tergus Pharma has announced plans to build a state-of-the-art commercial manufacturing facility in the Raleigh-Durham, NC area and will begin construction in July 2019. The new 100,000 square foot facility will have Clinical Trial Material (Phases I thru III) Supplies and commercial manufacturing capabilities and expand current capacity by over 400%. Tergus plans to open the new facility in early 2020, enabling the company to act as a CDMO by providing comprehensive services from development through manufacturing. This expansion comes as Targus announces a partnership with Great Point Partners which will provide the requisite funding. Learn More

A former GSK R&D site near Philadelphia is being redeveloped into a WeWork-styled campus for healthcare and life sciences firms, part of a plan to turn Pennsylvania into a more attractive research hub for the industry. The site was bought last year for a reported $50 million, and spans 1.6 million square feet. The bulk of that is in Upper Merion, where GSK has leased back space, while 640,000 square feet will be dedicated as a "coworking ecosystem."  Efforts to establish new R&D centers outside of the industry's traditional hubs in the Bay Area near San Francisco and Cambridge, Massachusetts, have been mostly mixed. Learn More

FUJIFILM has announced an initial $10 million investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at its FUJIFILM Diosynth Biotechnologies, Billingham, UK location. This perfusion-based facility represents the culmination of 3 years of in-house innovation by Fujifilm group companies and includes the introduction of patented, disruptive downstream bioprocessing technology to the biopharmaceutical industry. The new facility will include a 500L single use perfusion bioreactor and 7 patented downstream processing units which are expected to be available for process development services this Fall. Learn More

KD Pharma has acquired a manufacturing facility in Seal Sands, UK to manufacture omega-3 products. The site, which joins KD sites in Germany, Norway and the U.S., was previously used for manufacturing omega-3 products so is well positioned to be brought online later this year. The acquisition will enable KD Pharma to meet market demand for APIs in response to new product approvals, label expansions and clinical research. "This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s," said Oscar Groet, KD Pharma Group's chief executive. Learn More

Aldevron has announced plans to build a 14-acre gene therapy manufacturing campus at its headquarters in Fargo, North Dakota. Phase one of the construction project will start in August. Once completed, its annual capacity will be more than $1 billion of plasmid DNA, RNA, gene editing enzymes and other biologics. The expansion will increase biotech production capacity 10-fold, grow its warehouse space by more than four times, and develop a research and development center. The new construction will include three new buildings totaling 189,000 square feet. The first building is expected to be fully operational by the first quarter of 2021. Learn More

Iovance Biotherapeutics announced this week that it will build a 136,000-square-foot facility in Philadelphia to produce cancer therapies using its tumor-infiltrating lymphocyte (TIL) technology. While construction will take about two years, the California biotech expects to spend some $75 million over three years on the overall project, creating "several hundred" jobs in Philadelphia. Iovance received undisclosed financial incentives from the state, city and PIDC, a public-private economic development corporation, for the new site. It also has a letter of intent from PIDC for a five-year option to expand further. Learn More

Longmont city council members this week voted their unanimous initial approval of an ordinance authorizing the offer of an estimated $1.9 million in incentives to AveXis to get the company to expand its presence in Longmont. AveXis, a subsidiary of Novartis, recently bought the 64.12-acre former AstraZeneca property at 4000 Nelson Road, rehired 150 full-time former AstraZeneca employees and has begun operations there. Longmont's proposed $1.9 million incentives package would include rebates on certain costs and taxes on property, machinery and equipment.
Learn More

Boehringer Ingelheim has announced a multi-million-dollar investment that will see the expansion of its manufacturing capacity in Mexico over the next two years. The majority of the investment, $52 million will be at the biopharma giants site in Xochimilco which specializes in oral dosage anti-diabetic drugs. The Xochimilco plant is one of three sites that Boehringer has in Mexico, and the capital injection will be destined to increase the production capacity by at least 50%. The expansion at the Xochimilco plant is part of an investment plan to invest $84 million by 2023 to boost production at all three of its production sites in the country. Learn More

Chugai, a business unit of Roche, announced this week a decision to construct a centralized research laboratory. The new facility, to be known as the Chugai Life Science Park, is being constructed in Yokohama. The new facility will become home to both the Fuji Gotemba Research Laboratories and Kamakura Research Laboratories upon its completion. As for the future of the two research labs, both will be closed after the consolidation is complete. The new 380,000 sq. ft. facility is expected to cost roughly $1.15B with construction scheduled to begin in August of this year and be completed in Q3' 2022. Learn More

WuXi Biologics has announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. Under the LOI, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP) as well as Quality Control labs (QC). The facility will be dedicated to manufacture 100% of the global market of one of our partner's vaccine products. The value of the 20-year manufacturing contract is estimated to be more than $3 billion USD. Learn More

The University of Maryland BioPark is planning its next building as developer Wexford Science & Technology has revealed plans for a $200-plus million, 10-story, 333,000 sq. ft. office and biotech building at the northwest corner of Martin Luther King Blvd. and W. Baltimore St. The new building is Phase One of a two-phrase project that will redevelop a Poppleton/Hollins Market block that borders Martin Luther King Blvd., W. Baltimore St., W. Fayette St., and N. Fremont Ave. The project site currently includes green spaces, a parking lot, and several open spaces created by demolishing a Chinese carryout restaurant, rowhomes, and a former church. Learn More

Celltion Chairman Seo Jung-jin has announced that the biopharma group will invest roughly $34 billion and create some 110,000 jobs by 2030. These monies will be distributed so as to provide roughly $23 billion for its biopharma business, $4 billion for its APIs business and $7 billion for its U-Healthcare platform business which involves artificial intelligence and medical database services. The stated purpose of which being to build a bio-industrial valley capable of making South Korea the hub of the global biopharma industry. To realize this business plan, Celltrion says it will hire some 2,000 R&D professionals and 8,000 others for its expanded factories. Learn More

Thermo Fisher Scientific announced this week that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GSK for approximately $100 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex APIs. Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement and plans to expand use of the site to develop and produce complex APIs for other customers as well. The site contains 270,000 liters of reactor capacity, 10 production buildings, an R&D pilot plant and lab infrastructure. Learn More

The Delaware Biotechnology Institute will expand into 70,000 square feet within the new six-story, $160 million Biopharmaceutical Innovation Building on the STAR Campus next February. The building, which includes labs, offices, collaborative space, and shared research facilities, will be the home of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a coalition of 150 companies, educational institutions, nonprofits and state governments. The Delaware Biotechnology Institute will take a little over two floors of the six-story building besides the 70,000 square feet it has in its current location at 15 Innovation Way. Learn More

ElevateBio has announced plans to create and build a broad portfolio of single and multi-product cell and gene therapy companies. Leveraging the roughly $150 million it has raised to date, Elevate Bio plans to provide centralized bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug development and commercialization expertise. All of which will be housed in a new 100,000 sq. ft. R&D and Manufacturing center in Waltham, Massachusetts to be known as BaseCamp which is on schedule to be fully operational in Q3/Q4 of 2020.  In the meantime, the company is leveraging its lab space in Cambridge, Massachusetts to launch collaborations. Learn More

Bayer has made public plans to invest $150 million into its site in Berekeley, CA to build a Cell Culture Technology Center. The new Cell Culture Technology Center will be built on Bayer's existing Berkeley campus. The new 40,000 square foot facility, which is expected to be ready for clinical production in late 2021, will support the development of emerging therapies in Bayer's portfolio with an emphasis on oncology, cardiology and additional specialty care therapeutic areas. Bayer has selected Fluor for design and construction, and GE Healthcare for the integration of its FlexFactory™ technology platform into the Center. Learn More

Merck & Co., Inc., a publicly held global healthcare company known as MSD outside the United States and Canada, plans to invest up to $1 billion in stages over the next three years to expand its manufacturing operation in Elkton, Virginia. The company will add 120,000 square feet to its existing 1.1 million-square-foot operation in Elkton, Virginia to increase production of its Human Papillomavirus vaccines. Virginia successfully competed with other states for the project, which is anticipated to create approximately 100 new jobs in Rockingham County. As part of the expansion Blue Ridge Community College and James Madison University will collaborate to address Merck's short- and long-term workforce needs. Learn More

The Centre for Process Innovation (CPI) has collaborated on a project to develop new research and testing capabilities to drive further scale-up and manufacture of next generation liquid formulated products. Working alongside the Universities of Birmingham, Leeds and Edinburgh, CPI has created an open-access facility to enhance SME and larger corporate partners' product development. Consisting of a series of scaled vessels, from one liter to 1,000 liters, with a sample flow loop to allow in-line and at-line monitoring of process parameters, the facility's configuration is highly flexible and can be adjusted to specific project needs. Learn More

Biotechnology company Aldevron is expanding its Madison site, more than doubling the size of its space and, potentially, its staff over the next couple of years. The company currently occupies 8,000 square feet at 5602 Research Park Blvd., in University Research Park, and it will add nearly 10,000 square feet, moving into space being vacated by another biotech. Large fermentation equipment already has arrived to expand the site's biomanufacturing capacity. Aldevron's Madison labs culture bacteria, as well as mammal and insect cells, to manufacture proteins and enzymes. The expansion is expected to be completed and operating by this fall. Learn More

Takeda announced this week that it has opened a new research facility in San Diego. The new 165,000 square foot site is home to more than 250 employees focused on leveraging specialized drug discovery technologies and advancing discovery research in gastroenterology and neuroscience, the company said. In its announcement, Takeda said the San Diego site is home to four research platform groups -- structural biology, early target discovery, computational biology and biologics. The new San Diego facility complements Takeda's global Research & Development center in Cambridge, Mass. and its other global research site in Shonan, Japan. Learn More

Fujifilm Diosynth Biotechnologies has announced an expansion to its Billingham, United Kingdom location through the creation of a new BioCampus. The initial phase of this project will involve a new purpose-built facility. This will consist of approximately 42,000 square feet of space and will house roughly 250 existing staff and 50 new staffers. This latest investment is part of a major strategic growth plan. In September 2017 FDB announced the opening of the 10,000 square foot, state-of-the-art cell culture PD Labs in Wilton Centre, Teesside. In January 2019, the Wilton Laboratories were further expanded with the addition of 7,000 square feet of laboratory space increasing FDB's cell culture PD capacity. Learn More

Precigen this week announced the official opening of its new 5,000 sq. ft. manufacturing facility to support gene therapy manufacturing. The GMP facility was designed with agility and control in mind, focusing on rapid manufacturing and the ability to scale production appropriately to meet early stage clinical trial needs. The facility includes ISO 7 cleanroom suites that will be utilized to manufacture gene therapy vectors, as well as cell banks for early stage gene therapy trials. Due to the flexible design, other types of cell-based biopharma products can also be manufactured in the facility. Additionally, the facility includes a GMP quality control laboratory that supports lot release and stability testing. Learn More

GlaxoSmithKline has announced plans to spend $100 million to expand capacity at its Hamilton, Montana, site and boost production of vaccines, including Shingrix. The investment will create temporary construction and contracting jobs and a range of new permanent positions in science, engineering, manufacturing and quality control according to GSK. The biopharma giant is focusing the investment on components for adjuvants, which are added to vaccines to strengthen the immune response of patients. GSK is one of the few remaining large pharmaceutical makers in the vaccine market, along with Pfizer and Merck & Co. Learn More

Kite Pharma has announced plans to build a biologics manufacturing facility on a 20-acre site in Urbana, Maryland. The site, to be located at 9021 Bennett Creek Blvd just off I-270, will feature a 279,000 sq. ft. building to be home to as many as 800 employees. Alert readers will recall that Kite was acquired by Gilead in 2017 for nearly $12 billion and currently has facilities in both California and the Netherlands. While financial details of the project have not been made public, it is known that per the terms of its financial incentives Kite will spend no less than $85 million on project related expenditures. The project is expected to be completed in late 2021. Learn More

Start Codon, taking its name appropriately from a key messenger RNA (mRNA) sequence, will identify and recruit high potential companies from across the UK and beyond, drawing on the world-class resources of Cambridge's life sciences cluster to propel them towards a Series A fundraising. The accelerator says it will be the first in the Cambridge cluster to provide life science start-ups with significant investment, which it claims could reach up to $325,000. The site will have a full-time dedicated team of experienced and active mentors, and office and lab space, to be located at the Milner Therapeutics Institute, part of the new life sciences campus in central Cambridge. Learn More

The Summit Development Group, a Lake Oswego based real estate developer in Oregon, has announced a planned biotech campus on Sandy Boulevard in Southeast Portland. The site, to be known as NIR Center, will consist of two buildings, each roughly 10 stories tall, supporting 190,000 sq. ft. of BSL2 lab space and 65,000 sq. ft. of office, conference and event space. Planning for the site also includes 5,000 sq. ft. of retail space and the potential for a child care center. Learn More

GenScript Biotech has broken ground on construction of its Legend Biotech Commercial Manufacturing Center. The 1.4+ million sq. ft. Manufacturing Center is being built in compliance with the current cGMP requirements of the FDA, the EMEA and the NMPA, and will specialize in plasmids and viruses manufacturing. The plasmid service line will be equipped with single-use bioreactors for plasmid production, while regarding the virus line, suspension-based production processes and adherent production processes are planned. These production lines that feature a combined output capacity can simultaneously meet the demands of several commercial projects. Learn More

The Berkshire Innovation Center, a 20,000 sq. ft. two story facility in Pittsfield Massachusetts, is on track for a Fall opening. And with the construction running on schedule, officials are looking ahead to the next steps: attracting tenants to the building and surrounding William Stanley Business Park. Construction began in September on the $13.8 million center, which will include training facilities, biotech wet space, clean rooms and office and event space for small to medium-sized companies in the Berkshires. Its construction is considered to be a key part of the development of the mostly vacant 52-acre business park, which once was home to General Electric. Learn More

Paragon Bioservices is opening a manufacturing facility near Baltimore-Washington International Thurgood Marshall Airport that the company says will create 150 jobs. The biologics contract development and manufacturing organization said the new facility will help the firm employ 500 people in Maryland by the end of the year. The 200,000 sq. ft. facility has 500L and 2000L bioreactors that are used to produce materials used in gene therapy and next-generation vaccines. Learn More

Cambrex has announced that it has completed the construction of a $24 million highly potent API (HPAPI) manufacturing facility at its site in Charles City, IA. The 6,000 sq. ft. facility is currently undergoing validation and will be ready to commence customer projects in May 2019. The production area will contain 4 reactors ranging from 200 to 1,000 gallon capacity enabling manufacturing campaigns of batch sizes up to 300 kg. With the completion of this new facility, the Charles City site now has the flexibility to support all phases of development and offer all scales of HPAPI manufacture across the full OEL band spectrum. Learn More

Fresenius Kabi recently hosted a topping off ceremony to celebrate the $100 million expansion of its pharmaceutical manufacturing campus in Wilson, North Carolina.  The expansion will add at least 445 new jobs to the workforce of 100-plus at the Wilson County site by the time it's completed in 2022, increasing the company's production of affordable, generic medicines for use in hospitals and clinics. Alert readers will recall that Fresenius broke ground in September 2017 on a $250 million expansion at its pharmaceutical manufacturing site in Melrose Park, Il. Learn More

Bayer AG has made public plans to increase its presence in Cambridge, Massachusetts by upwards of 150 persons over the next three years. To facilitate its planned increased presence the biopharma giant has signed a 12-year lease for 62,100 square feet on the top two floors and a common area at 238 Main St. for a total of $100 million. With the additional expense of building laboratories and the cost of employee wages and benefits, Bayer is preparing to spend about $200 million, according to executives. The site is a 12-story building that is being constructed by the Massachusetts Institute of Technology with a focus on the development of cancer treatments. Learn More

Lonza has announced that it will partner with the Danish bioscience company Chr. Hansen in a joint venture to develop and produce bacteria-based therapies for biotech and pharma companies investing in the emerging field of microbiome research. The 50-50 partnership will be based in Basel, Switzerland, with facilities in both Switzerland and Denmark. To start, Lonza and Chr. Hansen will jointly invest $50.5 million. Once the partners confirm there's sufficient demand for supplying late-stage studies and commercial marketing, another $50 million in investment is planned. These monies will initially be used to upgrade existing facilities in Denmark and equipping new facilities in Switzerland. Learn More

Thermo Fisher is investing $150 million to upgrade three fill & finish sites, one in the U.S. and two in Italy. The U.S. site, located in Greenville, North Carolina, will receive an investment of $74 million to expand its prefilled syringe and vial-filling lines. The two sites in Italy, Monza and Ferentino, will roughly split the remaining $76 million to expand their prefilled syringe and vial-filling lines. Construction at all three sites is expected to be completed within the next 24 months.  The company says the expansions will especially support demand for sterile liquid and lyophilized product development and manufacturing. Learn More

AveXis has announced it signed an agreement to purchase an advanced biologics therapy manufacturing campus in Longmont, Colorado, further expanding AveXis' production capacity as it prepares to launch Zolgensma®. The Colorado facility joins AveXis' fully-operational manufacturing facility in Illinois, a facility under construction in North Carolina scheduled to be operational in 2020 and expanding product development capability at its San Diego facility. The addition of the six-building Longmont campus consists of nearly 700,000 square-feet of space for biologic drug manufacturing, offices, laboratories, warehousing and utilities. Learn More

Janssen Pharmaceuticals will demolish 76,000 square feet of research and lab space at its main building on its Route 202 campus in Raritan, New Jersey and replace it with a two-story 5,800-square-foot production addition. The new addition will be used for the relocation of existing production equipment. No word yet on what, if any, effect this will have on the number of workers at the site. This comes amid news that Janssen will be laying off roughly 50 employees at its site in Vacaville, California as It begins a three-year phaseout of the site that will ultimately result in its closure. The site was acquired decades ago when J&J purchased Alza for $10.5 billion. Learn More

Cambrex has announced it will double the liquid packaging capacity and weekly output at its Mirabel, Québec site in Canada with the addition of a cGMP packaging line and a new filler on the existing packaging line. By June 2019, the monthly capacity will be 1.2 million bottles compared with approximately 600,000 per month today. The new cGMP liquid packaging line allows the use of two fillers (XP and non-XP) working in parallel from process development through to cGMP commercial production and will now offer flexibility to accommodate ethanol and isopropanol-based solutions, aqueous solutions, lotions or suspensions. A new vision system has also been installed for online serialization. Learn More

Merck has made public plans to invest $168 million into its manufacturing site at Aubonne, Switzerland. The planned expansion will include a new building equipped with cutting-edge technologies dedicated to aseptic filling and quality control. The new lines for the aseptic filling of biotech medicines will be equipped with isolator technology, representing best practice in aseptic filling to ensure the safety of injectable medicines. One line will be dedicated to freeze-dried formulations, the other to liquid formulations. These two new lines, as well as the new quality control labs are expected to be completed in 2020 and 2021. Learn More.

Bluebird Bio has opened a 125,000 sq. ft. manufacturing facility in Durham, North Carolina. Once completed, the company will have invested more than $80 million building a world class site equipped with multiple manufacturing suites capable of producing lentiviral vector. The facility also includes warehouse and quality control testing laboratories. The facility construction is substantially complete and equipment qualification is underway. Initially, the company says it expects the facility to produce clinical and commercial supply of lentiviral vector near term and large enough to accommodate significant future expansion, including the possibility of manufacturing commercial drug product. Learn More

MaSTherCell has signed a lease for a 61,000-sq. ft. facility in Belgium which the contract manufacturer will build into a manufacturing site whose focus will be on late-stage and commercially-approved cell and gene therapy products. The new facility, expected to be operational in early 2021, will roughly triple the company's capacity, according to recent statements by parent company Orgenesis. The new facility will be located in the Gosselies Biopark, which is also home to the company's current facility which itself was updated in December of last year. Learn More

Mapi Pharma, which has developed a delayed release version of Teva's drug Copaxone, has announced that it will construct a manufacturing facility in Jerusalem. The new site, to be built even though the product has yet to receive formal marketing approval, is expected to have a total cost of roughly $12M and take a year to build. Mapi Pharma will use the several million dollars it receives from commercial partner Mylan, a well-known competitor of Teva's, to help pay for construction of the manufacturing facility that will employ 30 people. Learn More

Abeona Therapeutics says it has finished the first 6,000 square feet of a planned 26,000-foot expansion of a manufacturing facility in Cleveland, Ohio. The progress means the company should be ready to manufacture its EB-101 cell therapy for recessive dystrophic epidermolysis bullosa in time for a Phase 3 study starting mid-year. Abeona released the manufacturing progress report as part of its fourth quarter financial results. With biopharma companies often struggling to find contract manufacturing capacity for their complex therapies, Abeona is making a bet on in-house facilities. Learn More

Foundation Medicine is subleasing 64,000 sq. ft. from PTC at 121 Seaport in Massachusetts, and it is likely the launch of a bigger Seaport real estate play, according to brokerage documents. The Cambridge-based company was also looking at Cambridge Crossing, but it has since zeroed in on the Seaport, particularly WS Development's Seaport Square, sources say. With city approval on a 7.7 million sq. ft. building plan, WS has several available blocks in its Seaport portfolio, depending on Foundation's space requirements, which published reports say include 300,000 to 400,000 sq. ft. of labs. Learn More

BioMed Realty has acquired the Emeryville Center for Innovation, located in Emeryville, California, for approximately $135 million. The Emeryville Center for Innovation currently consists of a 250,000 square foot, six-story life science office building and adjacent developable land parcels. As part of the transaction, Novartis will enter into a one-year leaseback on the existing building, during which time BioMed Realty will advance redevelopment plans to transform the building into a Class A+, state-of-the-art multi-tenant laboratory and office facility with integrated tenant amenities. Learn More

The Indianapolis City-County Council this week approved granting Eli Lilly a tax abatement worth $7 million over the next 10 years, even though several council members expressed concern about the proposal. The council voted 19-6 to approve Lilly's request, which is tied to the firm's pledge to spend $91 million on a building at its Lilly Technology Center on Kentucky Avenue that will house the company's biosynthetic human insulin production operations after a renovation. Opposition to the tax abatement came amid concerns that the planned investment will not create new jobs at the site. Learn More

Sagent Pharmaceuticals, a division of Nichi-Iko Pharmaceutical Company, has announced the purchase of an FDA-approved manufacturing site in Raleigh, North Carolina, from Xellia Pharmaceuticals. The site is capable of approving both small-molecule drugs and biologics. While Sagent's chief executive officer (CEO), Peter Kaemmerer, Ph.D., said in a statement that while it intends to continue to manufacture some products for Xellia, the acquisition of the Raleigh site "will enable the production of lyophilized formulations of our future biosimilar product offerings." Learn More

Fujifilm has announced that it has entered into an agreement to acquire Biogen's site in Hillerod, Denmark for roughly $890M in cash. Upon closure of this transaction, Biogen Hillerod will become Fujifilm's fourth biopharmaceutical contract development and manufacturing site. The existing workforce at the site, which consists of approximately 800 employees, will be retained by Fujifilm. Biogen Hillerod is equipped with 6 x 15,000L bioreactors for the manufacture of cell culture derived biologics. This facility will significantly expand the capacity and capabilities of Fujifilm under its Saturn mAb services. Learn More

RK Pharma has signed a long-term lease for 82,795 square feet, Building 215 at the former Pfizer campus at 401 North Middletown Rd. The drug company signed a lease for the full building at the New York Center for Innovation in Pearl River, NY with the property owner Industrial Realty Group. RK Pharma plans to bring approximately 100 jobs to the formulations and manufacturing building. The company specializes in developing injectable and oral pharmaceuticals. Alert readers will recall that Industrial Realty group acquired the 1.993 million-square-foot, 207-acre campus from Pfizer in late 2015. Learn More

Gene therapy company Krystal Biotech will take the wraps off its initial 4,500-square-foot cGMP manufacturing center this week. Ancoris, the name of the new center, is where the company's gel-based medicine will be made as it pursues FDA approval for the ointment. The company employs about 35 people, but plans are underway to double its payroll with construction of a larger drug manufacturing facility, which will support anticipated commercial demand for Krystal products. While a location and size of the new facility has yet to be determined, the company says completion is anticipated by 2020. Learn More

High Purity New England has signed a lease for a substantial new building, formerly occupied by Alexion, where they will nearly quadruple their manufacturing footprint and expand their offices in northern Rhode Island. High Purity New England has seen a surge of growth in the past 6 years, having grown 80% year-over-year for the past 4 years. In addition to their new building, High Purity New England will continue to occupy their current office and production facility. Learn More

Amicus has made public plans for a 75,000 sq. ft. Global Research and Gene Therapy Center in the heart of Philadelphia, Pennsylvania. The site, which is expected to be home to 200+ biologists, chemists and others, is expected to be available for move-in later this year. The company's current corporate headquarters in Cranbury, New Jersey will remain in place with the new center in Philadelphia serving as the headquarters of the company's science organization and gene therapy leadership team. Currently, a couple of dozen Amicus researchers have moved into a short-term space in West Philadelphia as they await the move. Learn More

Allogene Therapeutics, maker of allogeneic T cell therapies, has leased a 118,000-square-foot space in Newark, California, to develop a manufacturing facility. The facility's production processes will meet good manufacturing practice standards and provide the clinical supply and commercial product for Allogene's cell therapies pending regulatory approval. Currently, the biotech gets its clinical trial supply through a contracting organization - though that should continue to be "a component of the company's long-term manufacturing strategy." The lease is expected to commence in March 2020. Learn More

The developers behind Watertown's Arsenal Yards project are seeking to swap uses in an 8- or 9- story building that sits at the south end of the site, overlooking the Charles River. Originally envisioned as a residential tower, Boylston Properties and The Wilder Cos. are proposing to change site G within the Arsenal Yards project to life sciences space. The updated proposal calls for an 8- or 9-story building to include around 155,000 square feet of office/lab space and a parking garage. The development team hopes to begin construction in spring 2020 with completion in 2022. Learn More

BioBridge Global has announced that it is setting up the second phase of its GenCure biomanufacturing program. The program, which will include clean rooms, labs, office and meeting space, will be located in a 21,000 sq. ft. facility located on East Houston Street in San Antonio, Texas. GenCure, a BioBridge subsidiary, specializes in human-cell and tissue services for regenerative medicine. The organization will initially employ 20 to 25 scientific and technical staff at the complex, construction of which broke ground this week and is expected to be completed by years end. Learn More

AveXis has announced plans to invest $60 million over the next two years to expand its presence in RTP, North Carolina. North Carolina Commerce Secretary Anthony Copeland joined local dignitaries and other officials at the North Carolina Biotechnology Center for the announcement of the expansion plan by AveXis, a gene-therapy firm. The company, which had been considering Dublin, Ireland as a possible location, plans to create upwards of 200 new jobs, the majority of which high paying in nature. Learn More

The Hudson Research Center at 619 West 54th Street, has signed a lease with HiberCell, a newly launched biotech company developing therapeutics focused on preventing cancer relapse and metastasis. HiberCell will occupy a 15,000 s/f pre-built wet lab and office suite on the building's 8th floor, which is under construction and expected to be completed in April. The space is part of the developers' larger initiative to create over 100,000 s/f of research space in the building over the next two years. The development of The Hudson Research Center aligns with the city's ongoing initiatives to expand Manhattan's life sciences sector. Learn More

The British Library has greenlit the construction of a new research hub on its property in North London. The new site, costing up to $1 Billion, will expand premises held by the British Library, which is next to King's Cross and the Francis Crick Institute, a well-known bioscience research center. This will add sorely needed space for biotech companies that want to operate in North London. Scheduled to be completed by 2025, the site will have up to 796,000 square feet of space for offices and labs. The construction costs will be covered by funding from the British Library and development companies Mitsui Fudosan and Stanhope. Learn More

Genexine and SCM Life Science this week announced the acquisition of North Carolina based Argos Therapeutics for $11.1 million. The acquisition agreement includes a 20,000 square feet cGMP cell therapy production facility. This facility, as well as associated researchers and intellectual property rights will resume business under the company name CoImmune. Alert readers will recall that Argos' lead drug had an unsuccessful Phase III trial that led to financial challenges resulting in this sale. Learn More

Amarin is moving its American headquarters from Bedminster to Route 22 in Bridgewater, New Jersey. The new 67,000+ sq. ft. space is located at 440 Route 22 in the Grande Commons development. This move is expected to occur over the summer of this year with Amarin intending to close it current Bedminster location. Alert readers will recall that Amarin has experienced strong growth following favorable clinical trial results for its FDA approved heart drug Vascepa. Learn More